Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for Prevention of Acute GvHD
NCT02683525Phase 2Completed
- Start
- Feb 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitagliptin in Acute Graft-Versus-Host Disease (aGvHD). Primary endpoint: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant at 100 days. Started Feb 2016; status: completed.
02
Drugs
sitagliptin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02683525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683525.